+ Filter
Loading...
A33
Loading...Anti-A33 Products
- Human Anti-A33 Recombinant Antibody (HPAB-0127-FY) (HPAB-0127-FY)
-
- Species Reactivity: VACV
- Type: Human IgG
- Application: ELISA, Neut, FuncS
Compare
- Anti-Human A33 Recombinant Antibody (F) (TAB-0625CLV)
-
- Type: Humanized antibody
Compare
- Anti-A33 Recombinant Antibody (HmAb A33) (TAB-0626CLV)
-
Compare
- Anti-Human A33 Recombinant Antibody Fab Fragment (A) (TAB-0620CLV-F(E))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody Fab Fragment (B) (TAB-0621CLV-F(E))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody (E) (TAB-0624CLV)
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody (KRN330) (TAB-002CL)
-
- Derivation: Human
- Species Reactivity: Human
- Type: Antibody
- Application: IHC
Compare
- Anti-Human A33 Recombinant Antibody (A) (TAB-0620CLV)
-
- Type: Humanized antibody
- Application: FC, IF
Compare
- Anti-Human A33 Recombinant Antibody (B) (TAB-0621CLV)
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody (C) (TAB-0622CLV)
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody (D) (TAB-0623CLV)
-
- Type: Humanized antibody
Compare
- Anti-A33 Recombinant Antibody scFv Fragment (HmAb A33) (TAB-0626CLV-S(P))
-
Compare
- Anti-Human A33 Recombinant Antibody scFv Fragment (A) (TAB-0620CLV-S(P))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody scFv Fragment (B) (TAB-0621CLV-S(P))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody scFv Fragment (C) (TAB-0622CLV-S(P))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody scFv Fragment (D) (TAB-0623CLV-S(P))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody scFv Fragment (E) (TAB-0624CLV-S(P))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody scFv Fragment (F) (TAB-0625CLV-S(P))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody Fab Fragment (C) (TAB-0622CLV-F(E))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody Fab Fragment (D) (TAB-0623CLV-F(E))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody Fab Fragment (E) (TAB-0624CLV-F(E))
-
- Type: Humanized antibody
Compare
- Anti-Human A33 Recombinant Antibody Fab Fragment (F) (TAB-0625CLV-F(E))
-
- Type: Humanized antibody
Compare
- Anti-A33 Recombinant Antibody Fab Fragment (HmAb A33) (TAB-0626CLV-F(E))
-
Compare
- Mouse Anti-A33 Recombinant Antibody; Fab Fragment (TAB-0629CLV-F(E)) (TAB-0629CLV-F(E))
-
- Species Reactivity: Human
- Type: Mouse Fab
- Application: ELISA, IHC
Compare
- Mouse Anti-A33 Recombinant Antibody; scFv Fragment (TAB-0629CLV-S(P)) (TAB-0629CLV-S(P))
-
- Species Reactivity: Human
- Type: Mouse scFv
- Application: ELISA, IHC
Compare
- Mouse Anti-A33 Recombinant Antibody (TAB-0629CLV) (TAB-0629CLV)
-
- Species Reactivity: Human
- Type: Mouse IgG
- Application: ELISA, IHC
Compare
- Human Anti-A33 Recombinant Antibody; scFv Fragment (HPAB-0127-FY-S(P)) (HPAB-0127-FY-S(P))
-
- Species Reactivity: VACV
- Type: Human scFv
- Application: ELISA
Compare
- Human Anti-A33 Recombinant Antibody; Fab Fragment (HPAB-0127-FY-F(E)) (HPAB-0127-FY-F(E))
-
- Species Reactivity: VACV
- Type: Human Fab
- Application: ELISA
Compare
View More Products
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Background
The A33 antigen is a cell surface glycoprotein that is highly expressed on the surface of most colorectal cancer cells, as well as in normal gastrointestinal epithelium. Due to it's limited expression in healthy tissue, and high expression on colorectal cancer it became a target for immunotherapy. The precise function of the A33 antigen is not yet fully understood, but it is thought to be involved in cell adhesion and signaling. The A33 antigen has become a target for monoclonal antibody-based therapies for colorectal cancer. Clinical trials have investigated the use of A33-targeted antibodies, either alone or conjugated with radioisotopes or cytotoxic drugs, for the treatment of colorectal cancer. Continued research is focused on optimising A33 antigen based therapies.
